Ohr Pharmaceutical is a pharmaceutical company focused on the clinical development of new drugs to address underserved therapeutic needs in markets that are large and growing. The company is currently focused on two lead compounds: Squalamine eye drops for treating the wet form of age-related macular degeneration, and OHR/AVR118 for treating cancer cachexia, which is currently being investigated in a Phase II trial. For more information, visit the company’s Web site at www.ohrpharmaceutical.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: